Stefan Zeuzem
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
Dietz J, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C, Buggisch P, Matschenz K, Spengler U, Mullhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, European HCV Resistance Study Group. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clin Gastroenterol Hepatol 2019
06.11.2019Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
06.11.2019Clin Gastroenterol Hepatol 2019
Dietz Julia, Backhus Johanna, Zizer Eugen, Boettler Tobias, Neumann-Haefelin Christoph, Semela David, Stauber Rudolf, Berg Thomas, Berg Christoph, Zeuzem Stefan, Vermehren Johannes, Sarrazin Christoph, Buggisch Peter, Matschenz Katrin, Spengler Ulrich, Mullhaupt Beat, Schulze Zur Wiesch Julian, Piecha Felix, Mauss Stefan, Seegers Barbara, Hinrichsen Holger, Antoni Christoph, Wietzke-Braun Perdita, Peiffer Kai-Henrik, Berger Annemarie, European HCV Resistance Study Group
Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study
Kolly P, Waidmann O, Vermehren J, Moreno C, Vögeli I, Berg T, Semela D, Zeuzem S, Dufour J. Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. J Hepatol 2017; 67:876-878.
19.07.2017Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study
19.07.2017J Hepatol 2017; 67:876-878
Kolly Philippe, Waidmann Oliver, Vermehren Johannes, Moreno Christophe, Vögeli Isabelle, Berg Thomas, Semela David, Zeuzem Stefan, Dufour Jean-François
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
Berg T, Sarrazin C, Neumann K, Zankel M, Balk H, Buggisch P, Spengler U, Gerlach T, Hinrichsen H, Rasenack J, Möller B, Klinker H, Teuber G, Weich V, Zeuzem S. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (Baltimore, Md.) 2009; 50:369-77.
01.08.2009Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients
01.08.2009Hepatology (Baltimore, Md.) 2009; 50:369-77
Berg Thomas, Sarrazin Christoph, Neumann Konrad, Zankel Myrga, Balk Heike, Buggisch Peter, Spengler Ulrich, Gerlach Tilman, Hinrichsen Holger, Rasenack Jens, Möller Bernd, Klinker Hartwig, Teuber Gerlinde, Weich Viola, Zeuzem Stefan
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
Kronenberger B, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Buggisch P, Gerlach T, Hinrichsen H, Herrmann E, Berg T, Zeuzem S. Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial. European journal of gastroenterology & hepatology 2007; 19:639-46.
01.08.2007Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial
01.08.2007European journal of gastroenterology & hepatology 2007; 19:639-46
Kronenberger Bernd, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Herrmann Eva, Berg Thomas, Zeuzem Stefan
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Berg T, Alshuth U, Martus P, Spengler U, Klinker H, Kallinowski B, Schmidt W, Pape G, Rasenack J, Goeser T, Buggisch P, Gerlach T, Heintges T, Sarrazin C, Nasser S, von Wagner M, Zeuzem S. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130:1086-97.
01.04.2006Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
01.04.2006Gastroenterology 2006; 130:1086-97
Berg Thomas, Alshuth Ulrich, Martus Peter, Spengler Ulrich, Klinker Hartwig, Kallinowski Birgit, Schmidt Wolfgang E, Pape Gerd R, Rasenack Jens, Goeser Tobias, Buggisch Peter, Gerlach Tilman, Heintges Tobias, Sarrazin Christoph, Nasser Samer, von Wagner Michael, Zeuzem Stefan
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
von Wagner M, Herrmann E, Häussinger D, Bernsmeier C, Bergk A, Heintges T, Rasenack J, Hinrichsen H, Berg T, Huber M, Zeuzem S. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
01.08.2005Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C
01.08.2005Gastroenterology 2005; 129:522-7
von Wagner Michael, Herrmann Eva, Häussinger Dieter, Bernsmeier Christine, Bergk Alexandra, Heintges Tobias, Rasenack Jens, Hinrichsen Holger, Berg Thomas, Huber Miriam, Zeuzem Stefan
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, Zeuzem S. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?. Hepatology (Baltimore, Md.) 2004; 39:1456-7; author reply 1457-8.
01.05.2004Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?
01.05.2004Hepatology (Baltimore, Md.) 2004; 39:1456-7; author reply 1457-8
Berg Thomas, Sarrazin Christoph, Hinrichsen Holger, Buggisch Peter, Gerlach Tilman, Zachoval Reinhart, Zeuzem Stefan
Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
Berg T, Hopf U, Pape G, Wursthorn K, Nasser S, Goeser T, Spengler U, Herrmann E, Buggisch P, Gerlach T, Hinrichsen H, Kronenberger B, Zeuzem S. Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial. Hepatology (Baltimore, Md.) 2003; 37:1359-67.
01.06.2003Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial
01.06.2003Hepatology (Baltimore, Md.) 2003; 37:1359-67
Berg Thomas, Hopf Uwe, Pape Gerd R, Wursthorn Karsten, Nasser Samer, Goeser Tobias, Spengler Ulrich, Herrmann Eva, Buggisch Peter, Gerlach Tilman, Hinrichsen Holger, Kronenberger Bernd, Zeuzem Stefan
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, Hopf U, Zeuzem S. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (Baltimore, Md.) 2003; 37:600-9.
01.03.2003Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy
01.03.2003Hepatology (Baltimore, Md.) 2003; 37:600-9
Berg Thomas, Sarrazin Christoph, Herrmann Eva, Hinrichsen Holger, Gerlach Tilman, Zachoval Reinhart, Wiedenmann Bertram, Hopf Uwe, Zeuzem Stefan
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers
Jung M, Zeuzem S, Trojan J, Whitehead E, Birtles E, Bailey J, Page M, Schirren C, Diepolder H, Gerlach T, Schraut W, Zachoval R, Grüner N, Pape G. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 2002; 20:3598-612.
04.10.2002Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers
04.10.2002Vaccine 2002; 20:3598-612
Jung Maria-Christina, Zeuzem Stefan, Trojan Jörg, Whitehead Eve, Birtles Emma, Bailey John, Page Mark, Schirren Carl-Albrecht, Diepolder Helmut, Gerlach Tilman, Schraut Winfried, Zachoval Reinhart, Grüner Norbert, Pape Gerd R